Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Application of New Molecular Probes in the Diagnosis and Treatment...
share announcement

Application of New Molecular Probes in the Diagnosis and Treatment of Malignant Tumors

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 6320

Special Issue Editors

Dr. Hui Lu

E-Mail Website
Guest Editor
Department of Orthopedics, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Interests: hand tumor; peripheral nerve tumor; malignant skin tumor; novel therapies
Dr. Dengfeng Cheng

E-Mail Website
Guest Editor
Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Interests: molecular imaigng; molecular probes design; cancer diagnosis and treatment; cardiovasular imaging; neuroimaging

Special Issue Information

Dear Colleagues,

With the processive growth and aging of the population, the global incidence of cancer is gradually increasing, which continues to impose a heavy socio-economic burden to affected individuals. The advent of the era of precision medicine has brought new opportunities and challenges. Two important points to save the lives and improve the quality of life of malignant tumor patients are: 1. early diagnosis and treatment; 2. appropriate treatment plans. Molecular probes have countermeasures for both of these key points.

Molecular probes are divided into different types of probes, such as nuclear medicine, optical, magnetic, acoustic, photoacoustic, etc., which are the prerequisite and core technologies for realizing molecular imaging. In recent years, this technology has developed rapidly, and some molecular probes have been clinically transformed. The multimodal molecular imaging of tumors can detect tumors at an early stage, support clinical staging, guide the decision-making of clinical drugs and surgical treatment, and predict and evaluate the effect of cancer treatment. The growing research of some molecular probes with the integration of diagnosis and treatment not only enables the diagnosis and staging the tumor, but also provides personalized treatment for the specific target of the tumor, providing a new strategy for tumor diagnosis and treatment.

The "destructive" and "one size fits all" treatment methods of malignant tumors often cause a serious waste of medical resources and affect patient quality of life. Targeted drug specific therapy has the advantages of less trauma, less complications and good prognosis, and has gradually become a hot spot in the field of tumor therapy.

This Special Issue aims to stimulate the discussion of new developments and discoveries in the field of molecular probes for the diagnosis and treatment of malignant tumors. We welcome both reviews and research articles on topics including specific molecular probes for malignant tumor imaging, new discoveries in targeted therapy for malignant tumors, recent advances in targeted imaging and therapy for malignant tumors, and the future of molecular probe technology for malignant tumors.

I look forward to receiving your contributions.

Dr. Hui Lu
Dr. Dengfeng Cheng
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • malignant tumors
  • molecular probes
  • early diagnosis
  • PET/CT (MRI)
  • novel therapies
  • SPECT
  • optical imaging
  • ultrasonoscopy
  • nanoprobe
  • radiology

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research

3 pages, 170 KiB  
Editorial
Application of New Molecular Probes in the Diagnosis and Treatment of Malignant Tumors
by Dengfeng Cheng and Hui Lu
Cancers 2023, 15(19), 4752; https://doi.org/10.3390/cancers15194752 - 27 Sep 2023
Viewed by 551
Abstract
Molecular probes, specialized tools or substances meticulously designed to bind to specific molecules or biomarkers within cells, tissues, or biological samples, play a pivotal role in various domains such as biomedical research, diagnostics, and medical treatments [...] Full article
(This article belongs to the Special Issue Application of New Molecular Probes in the Diagnosis and Treatment of Malignant Tumors)

Research

Jump to: Editorial

15 pages, 12610 KiB  
Article
Validation of the DNA Methylation Landscape of TFF1/TFF2 in Gastric Cancer
by Ze Qian, Yifan Jiang, Chunhui Shou, Jinghua Yu, Dongdong Huang, Haiyang Xie, Lin Zhou, Diyu Chen and Shusen Zheng
Cancers 2022, 14(22), 5474; https://doi.org/10.3390/cancers14225474 - 08 Nov 2022
Cited by 5 | Viewed by 1394
Abstract
As one of the most frequently occurring tumor types, the increasing incidence of gastric cancer (GC) has been observed in the past decades. The recent studies have illustrated that epigenetic modifications mediated by DNA methyltransferases (DNMTs) are the major epigenetic hallmark in GC [...] Read more.
As one of the most frequently occurring tumor types, the increasing incidence of gastric cancer (GC) has been observed in the past decades. The recent studies have illustrated that epigenetic modifications mediated by DNA methyltransferases (DNMTs) are the major epigenetic hallmark in GC progression. Nowadays, DNA methylation was considered to be necessary for inducing the silence of tumor suppressor genes (TSGs). As an important group of peptides, the TFF family has been confirmed to function as a TSG in various kinds of cancers. However, whether TFFs could be modified by DNA methylation in gastric cancer remains unknown. Here, we initially screened out two transcriptional sequencing profiles about GC from Gene Expression Omnibus (GEO) database. The lower expression levels of TFF1 and TFF2 were observed in GC tumor tissues as compared to those in normal tissues. Additionally, utilizing the Kaplan–Meier analysis, the expressions of TFF1 and TFF2 were identified to be associated with the prognosis of GC patients. Subsequently, the integrative analysis was performed to estimate the DNA methylation level of each site in TFF1/TFF2 CpG islands. Importantly, our findings indicated that hyper-methylation of cg01886855 and cg26403416 were separately responsible for the downregulation of TFF1 and TFF2 in GC samples. In addition, utilizing the experiments in vitro, we demonstrated that TFF1/TFF2 could suppress the proliferation of GC cells. Based on these results, we suspected that TFF1/TFF2 could potentially act as the putative tumor suppressor in GC, and these two TFFs were of great value for predicting the overall survival (OS) status in the gastric cancer cohort. Totally, our findings revealed a potential therapeutic method for targeting the TFFs for the treatment of GC. Full article
(This article belongs to the Special Issue Application of New Molecular Probes in the Diagnosis and Treatment of Malignant Tumors)
►▼ Show Figures

Figure 1

14 pages, 1625 KiB  
Article
Neoadjuvant Chemotherapy Followed by Radiofrequency Ablation May Be a New Treatment Modality for Colorectal Liver Metastasis: A Propensity Score Matching Comparative Study
by Yizhen Chen, Yurun Huang, Linwei Xu, Jia Wu, Fang Han, Hang Jiang, Pengwen Zheng, Dong Xu and Yuhua Zhang
Cancers 2022, 14(21), 5320; https://doi.org/10.3390/cancers14215320 - 28 Oct 2022
Cited by 4 | Viewed by 1416
Abstract
Background: Most colorectal liver metastases (CRLM) are not candidates for liver resection. Radiofrequency ablation (RFA) plays a key role in selected CRLM patients. Neoadjuvant chemotherapy (NAC) followed by liver resection has been widely used for resectable CRLM. Whether NAC followed by radiofrequency ablation [...] Read more.
Background: Most colorectal liver metastases (CRLM) are not candidates for liver resection. Radiofrequency ablation (RFA) plays a key role in selected CRLM patients. Neoadjuvant chemotherapy (NAC) followed by liver resection has been widely used for resectable CRLM. Whether NAC followed by radiofrequency ablation (RFA) can achieve a similar prognosis to NAC followed by hepatectomy remains is unclear. The present study aimed to provide a new treatment modality for CRLM patients. Methods: This comparative retrospective research selected CRLM patients from 2009 to 2022. They were divided into NAC + RFA group and NAC + hepatectomy group. The propensity score matching (PSM) was used to reduce bias. We used multivariate cox proportional hazards regression analysis to explore independent factors affecting prognosis. The primary study endpoint was the difference in the progression-free survival (PFS) between the two groups. Results: A total of 190 locally curable CRLM patients were in line with the inclusion criteria. A slight bias was detected in the comparison of basic clinical characteristics between the two groups. RFA showed a significant advantage in the length of hospital stay (median; 2 days vs. 7 days; p < 0.001). The 1- and 3-year PFS in the liver resection and the RFA groups was 57.4% vs. 86.9% (p < 0.001) and 38.8% vs. 55.3% (p = 0.035), respectively. The 1-year and 3-year OS in the liver resection and RFA groups was 100% vs. 96.7% (p = 0.191) and 73.8% vs. 73.6% (p = 0.660), respectively. Conclusions: NAC followed by RFA has rapid postoperative recovery, fewer complications, and better prognosis. Full article
(This article belongs to the Special Issue Application of New Molecular Probes in the Diagnosis and Treatment of Malignant Tumors)
►▼ Show Figures

Figure 1

19 pages, 4535 KiB  
Article
Genome-Wide DNA Methylation and Gene Expression Profiling Characterizes Molecular Subtypes of Esophagus Squamous Cell Carcinoma for Predicting Patient Survival and Immunotherapy Efficacy
by Yulong Zheng, Qiqi Gao, Xingyun Su, Cheng Xiao, Bo Yu, Shenglin Huang, Yifeng Sun, Sheng Wu, Yixin Wo, Qinghua Xu, Nong Xu and Hui Yu
Cancers 2022, 14(20), 4970; https://doi.org/10.3390/cancers14204970 - 11 Oct 2022
Cited by 5 | Viewed by 1960
Abstract
Background: Immunotherapy is recently being used to treat esophageal squamous cell carcinoma (ESCC); however, response and survival benefits are limited to a subset of patients. A better understanding of the molecular heterogeneity and tumor immune microenvironment in ESCC is needed for improving disease [...] Read more.
Background: Immunotherapy is recently being used to treat esophageal squamous cell carcinoma (ESCC); however, response and survival benefits are limited to a subset of patients. A better understanding of the molecular heterogeneity and tumor immune microenvironment in ESCC is needed for improving disease management. Methods: Based on the DNA methylation and gene expression profiles of ESCC patients, we identify molecular subtypes of patients and construct a predictive model for subtype classification. The clinical value of molecular subtypes for the prediction of immunotherapy efficacy is assessed in an independent validation cohort of Chinese ESCC patients who receive immunotherapy. Results: We identify two molecular subtypes of ESCC (S1 and S2) that are associated with distinct immune-related pathways, tumor microenvironment and clinical outcomes. Accordingly, S2 subtype patients had a poorer prognosis. A 15-gene expression signature is developed to classify molecular subtypes with an overall accuracy of 94.7% (89/94, 95% CI: 0.880–0.983). The response rate of immunotherapy is significantly higher in the S1 subtype than in the S2 subtype patients (68.75% vs. 25%, p = 0.028). Finally, potential target drugs, including mitoxantrone, are identified for treating patients of the S2 subtype. Conclusions: Our findings demonstrated that the identified molecular subtypes constitute a promising prognostic and predictive biomarker to guide the clinical care of ESCC patients. Full article
(This article belongs to the Special Issue Application of New Molecular Probes in the Diagnosis and Treatment of Malignant Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop